We describe a kinase-independent function of CDK8 in hematopoietic tumors and suggest that the proteasome-induced degradation of CDK8 in combination with inhibition of mTOR might represent an addition to the therapeutic armory. Here, CDK8 is linked to hematopoietic and lymphoid cell neoplasm.